Chester County News and Community Website
HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) has announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab) for the treatment of adults with moderately to severely …
FDA Approves TREMFYA® for Crohn’s Disease, Offering New Treatment Options Read More
NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) shared encouraging findings on its investigational antiviral drug, tivoxavir marboxil (TXM), during the International Society for Antiviral Research (ICAR 2025) in Las Vegas. …
Traws Pharma Unveils Promising Bird Flu Treatment Data Read More
HORSHAM, PA — STRATA Skin Sciences, Inc. (NASDAQ: SSKN) has announced the results of a groundbreaking study conducted in Japan, which underscores the technological advantages of its XTRAC® Excimer Laser over …
Study Validates Advantages of STRATA Skin Sciences’ XTRAC Laser Technology Read More
PLYMOUTH MEETING, PA — The National Comprehensive Cancer Network® (NCCN®) has released a free, on-demand webinar titled “Why Should I Consider a Clinical Trial?” to address common questions and misconceptions about …
NCCN Launches Free On-Demand Webinar on Cancer Clinical Trials Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced progress in its Phase 1 clinical trial for OCU200, a novel biologic designed to treat diabetic macular edema (DME) and related eye conditions. …
Ocugen Advances OCU200 Clinical Trial Amid Promising Safety Results Read More
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced that its Phase 2 Advance-HTN trial data will be presented during a late-breaking clinical trials session at the American College of …
Mineralys Therapeutics to Present Phase 2 Advance-HTN Trial Data at ACC.25 Read More
AUSTIN, TX & PHILADELPHIA, PA — Faeth Therapeutics and The GOG Foundation, Inc. have announced a significant milestone in the fight against endometrial cancer. The first patient has been dosed in …
Faeth Therapeutics and GOG Foundation Launch Pioneering Phase 2 Trial for Advanced Endometrial Cancer Read More
PHILADELPHIA, PA — iECURE, Inc. has announced that early data from its Phase 1/2 OTC-HOPE clinical trial, evaluating the gene-editing candidate ECUR-506 for neonatal onset ornithine transcarbamylase (OTC) deficiency, will be …
iECURE to Present Promising Initial Data from Gene Editing Trial for Neonatal OTC Deficiency Read More
WILMINGTON, DE — NiKang Therapeutics® Inc. has achieved a pivotal step in the development of its first-in-class CDK2 degrader, NKT3964, by completing the dosing of the first patient cohort in a …
NiKang Advances CDK2 Degrader with Key Milestone in Cancer Treatment Trial Read More
PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has announced notable interim findings from a Phase 1 clinical trial testing DNA-encoded monoclonal antibodies (DMAbs) for COVID-19. Impressively, 100% of participants who reached …
INOVIO Reports Groundbreaking Results in COVID-19 Antibody Trial Read More